Abdi BOZKURT, Ayhan USAL, Mustafa DEMİRTAŞ, Abdullah CANATAROĞLU

Kalp yetersizliğinde tümör nekroz faktör-alfa düzeyinin değerlendirilmesi

AMAÇ: Kalp yetersizliğinde (KY) tümör nekroz faktör-alfa (TNF-alfa) serum düzeyinin artmasının hastalığın prognostik belirleyicilerinden biri olduğu belirtilmektedir. Bu çalışmada, iskemik ve idiyopatik dilate kardiyomiyopatili hastalarda serum TNF-alfa düzeyinin saptanması ve bu düzeyin hastaların ejeksiyon fraksiyonu (EF) ile ilişkisinin olup olmadığının değerlendirilmesi amaçlandı. YÖNTEM: Çalışmaya KY olan 30 (16 erkek, 14 kadın; yaş ortalaması 49.0±14.58 yıl) hasta ile kontrol grubu olarak 20 (10 erkek, 10 kadın; yaş ortalaması 53.85±9.87yıl) sağlıklı birey alındı. SONUÇLAR: KY olan hastaların ortalama TNF-alfa düzeyleri 70.848±91.800 pikogram/mililitre (pg/ml), kontrol grubunun ise 19.915±5.567 pğ/ml olarak tesbit edildi (p

Evaluation of serum TNF-alpha levels in heart failure

PURPOSE: Increased serum level of tumor necrosis factor-alpha (TNF-alpha) in heart failure (HF) is suggested as a prognostic marker of the disease.-The detection of serum levels of TNF-alpha in ischemic and idiopathic dilated cardiomyopathy and the evaluation of relationbetween serum TNF-alpha levels and ejection fraction (EF) are aimed in this study. METHODS: Thirty patients (16 male, 14 female; mean age 49.0±14.58 years) with HF and 20 healthy controls (10 male, 10 female; mean age 53.85±9.87 years) were included in the study. RESULTS: Levels of serum TNF-alpha were found as 70.848+91.800 pg/ml in the patients with HF and 19.915±5.567 pg/ml in the healthy controls (p

PDF

___

1. Baig MK, Mahon M, McKenna WJ, et al: Managing the patient with heart failure. Am Heart J 1998; 135:216-230.
2. Barath P, Fishbein MC, Cao J, et al: Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65: 297-302.
3. Beutler B, Krochin N, Milsark IW, et al: Control of cachectin (tumor necrosis factor) synthesis: Mechanism of endotoxin resistance. Science 1986;232: 977-980.
4. Bryant D, Becker L, Richardson J, et al: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor. Circulation 1998;97:1375- 1380.
5. Dutka DP, Elborn JS, Delamera F, et al: Tumor necrosis factor alpha in severe congestive cardiac failure. Br Heart J 1993;70:141-143.
6. Ekmekçi A: Patolojik yeni yapılanma: Remodeling. Konjestif Kalp Yetmezliği Tedavisine Patofizyolojik Yaklaşım, Ekmekci A (ed.s), İstanbul, 1996, 48.
7. Fuchs D, Samsonow M, Tilz GP, et al. Stimulated cellular immune system in patients with congestive heart failure. Eur J Clin Chem Clin Biochem 1993;31:111-114.
8. Giroir BP, Johnson JH, Brown T, et al: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992;90: 693-698.
9. Habib FM, Springall DR, Davies GJ; et al: Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347: 1151- 1155.
10. Hattler BG, Zeevl A, Oddis CV, et al: Cytokine induction during cardic surgery: analysis of TNF-alpha expression pre- and postcardiopulmonary by-pass. J Card Surg 1995;10:418-422.
11. Katz SD, Rao R, Berman JW, et al: Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Circulation 1994;90:12-16.
12. Krown KA, Page MT, Nguyen C, et al: Tumor necrosis factor alpha- induced apopitosis in cardiac myocytes: involvement of the sphingolipid cascade in cardiac cell death. J Clin Invest 1996;98: 2854-2865.
13. Levine B, Kalman J, Mayer L, et al: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 1990;323:236- 241.
14. Marriot JG, Goldman JH, Keeling PJ, et al: Abnormal cytokine levels in idiopathic dilated cardiomyopathy correlate with prognosis. Heart 1995;75: 287-290.
15. Matsumori A, Yamada T, Suzuki H, et al: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72: 561-566.
16. Mc Kee PA, Castelli WP, Mc Namara PM, et al: The natural history of congestive heart failure: The Framingham study. N Eng J Med 1971;285: 1441.
17. Mc Murray J, Abdullah İ, Dargie HJ, Shapiro D: Increased concentrations of tumor necrosis factor in “chacectic” patients with severe chronic heart failure. Br Heart J 1991;66:356-368.
18. Michie HR, Manogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Eng J Med 1988;318:1481-1486.
19. Pennica D, Nedwin GE, Hayflick JS, et al: Human tumor necrosis factor: precursor, structure, expression and homology to lymphotoxin. Nature 1984;312: 724-729.
20. Torre-Aminone G, Kapadia S, Lee J, et al: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-1493.
21. Torre-Aminone G, Kapadia S, Lee J, et al: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93: 704-711.
22. Tracey KJ, Beutler B, Lowry SF: Shock and tissue injury induced by recombinant human cachectin. Science 1986;231: 470-474.
23. Vaddi K, Nicolini FA, Mehta P, et al: Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Circulation 1994;90: 694-699.
24. Yokohama T, Nakano M, Bednarczyk JL, et al: Tumor necrosis factor-alpha provokes a hypertrophic response in adult cardiac myocytes. Circulation 1997;95: 1247-1252.